製品: caspase12 Antibody
カタログ: AF5199
タンパク質の説明: Rabbit polyclonal antibody to caspase12
アプリケーション: WB IHC
反応性: Human, Rat
分子量: 38 kDa; 39kD(Calculated).
ユニプロット: Q6UXS9
RRID: AB_2837685

類似製品を見る>>

   サイズ 価格 在庫状況
 100ul $280 在庫あり
 200ul $350 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先

製品説明

ソース:
Rabbit
アプリケーション:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Rat
クローナリティ:
Polyclonal
特異性:
caspase12 Antibody detects endogenous levels of total caspase12.
RRID:
AB_2837685
引用形式: Affinity Biosciences Cat# AF5199, RRID:AB_2837685.
コンジュゲート:
Unconjugated.
精製:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ/展開

CASP 12; CASP-12; Casp12; CASP12P1; caspase 12 (gene/pseudogene); caspase 12 pseudogene 1; CASPC_HUMAN; Inactive caspase-12; OTTHUMP00000207032;

免疫原

免疫原:
Uniprot:
遺伝子(ID):
発現特異性:
Q6UXS9 CASPC_HUMAN:

Detected in heart, kidney, liver, lung, pancreas, small intestine, spleen, stomach, thymus and testis.

タンパク質の説明:
Has no protease activity. May reduce cytokine release in response to bacterial lipopolysaccharide during infections. Reduces activation of NF-kappa-B in response to TNF
タンパク質配列:
MADEKPSNGVLVHMVKLLIKTFLDGIFDDLMENNVLNTDEIHLIGKCLKFVVSNAENLVDDITETAQIAGKIFREHLWNSKKQLSSDISSDGEREANMPGLNIRNKEFNYLHNRNGSELDLLGMRDLLENLGYSVVIKENLTAQEMETALRQFAAHPEHQSSDSTFLVFMSHSILNGICGTKHWDQEPDVLHDDTIFEIFNNRNCQSLKDKPKVIIMQACRGNGAGIVWFTTDSGKASADTHGRLLQGNICNDAVTKAHVEKDFIAFKSSTPHNVSWRHETNGSVFISQIIYYFREYSWSHHLEEIFQKVQHSFETPNILTQLPTIERLSMTRYFYLFPGN

PTMs - Q6UXS9 基板として

Site PTM Type Enzyme
T142 Phosphorylation

研究背景

機能:

Has no protease activity. May reduce cytokine release in response to bacterial lipopolysaccharide during infections. Reduces activation of NF-kappa-B in response to TNF.

組織特異性:

Detected in heart, kidney, liver, lung, pancreas, small intestine, spleen, stomach, thymus and testis.

タンパク質ファミリー:

Belongs to the peptidase C14A family.

研究領域

· Cellular Processes > Cell growth and death > Apoptosis.   (View pathway)

· Genetic Information Processing > Folding, sorting and degradation > Protein processing in endoplasmic reticulum.   (View pathway)

· Human Diseases > Neurodegenerative diseases > Alzheimer's disease.

· Human Diseases > Neurodegenerative diseases > Amyotrophic lateral sclerosis (ALS).

· Human Diseases > Neurodegenerative diseases > Prion diseases.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Organismal Systems > Immune system > NOD-like receptor signaling pathway.   (View pathway)

参考文献

1). The potential immunotoxicity of fine particulate matter based on SD rat spleen. ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH (PubMed: 31218585) [IF=5.8]

Application: WB    Species: rat    Sample: spleen

Fig. 4 |PM2.5 exposure induce ERS via the apoptosis of spleen.a, b The levels of spleen caspase12 and CHOP mRNA were measured using qRT-PCR in summer and winter PM2.5 treatment in SD rats. c, d Western blot assays were used to detect the protein levels of caspase-12 and CHOP in spleen by summer PM2.5 treated and quantification of analysis.

2). Nucleotide-binding oligomerization domain protein 1 enhances oxygen-glucose deprivation and reperfusion injury in cortical neurons via activation of endoplasmic reticulum stress-mediated autophagy. EXPERIMENTAL AND MOLECULAR PATHOLOGY (PubMed: 32888957) [IF=3.6]

Application: WB    Species: rat    Sample: cortical neurons

Fig. 4. |Effect of NOD1 down-regulation on ER stress in OGD/R-treated cortical neurons. After infection with NOD1 knockdown lentiviruses, primary rat cortical neurons were treated with OGD for 2 h and reoxygenation for 24 h. Relative expressions of CHOP, cleaved-caspase-12 and cleaved-caspase-3 were assessed using western blotting. Relative expression of proteins (protein/GAPDH) in each group was normalized to that in Control group. Data were expressed as mean ± SD (n = 3).

3). Therapeutic effects of scavenger receptor MARCO ligand on silica-induced pulmonary fibrosis in rats. TOXICOLOGY LETTERS (PubMed: 31028789) [IF=3.5]

Application: WB    Species: rat    Sample: lung

Fig. 4. |MARCO antagonism suppressed the UPR pathways and ERS-related apoptosis. (A) The expression levels of and ERS and UPR pathway related proteins in lung tissues were measured by Western blot analysis.

4). Inonotus obliquus extract alleviates myocardial ischemia/reperfusion injury by suppressing endoplasmic reticulum stress. Molecular Medicine Reports (PubMed: 33236154) [IF=3.4]

Application: WB    Species: rat    Sample: myocardium

Figure 6.| Expression of SIRT1, GRP78, p‑PERK, p‑eIF2α, CHOP, caspase‑12 and the mRNA levels of caspase‑12 in the myocardium. (A) Representative blots of SIRT1, GRP78, p‑PERK, p‑eIF2α, CHOP and caspase‑12. Semiquantitative analysis of (B) SIRT1, (C) GRP78, (D) p‑PERK, (E) p‑eIF2α, (F) CHOP and (G) caspase‑12.

Application: WB    Species: Rat    Sample: myocardium

Figure 6. Expression of SIRT1, GRP78, p-PERK, p-eIF2α, CHOP, caspase-12 and the mRNA levels of caspase-12 in the myocardium. (A) Representative blots of SIRT1, GRP78, p-PERK, p-eIF2α, CHOP and caspase-12. Semiquantitative analysis of (B) SIRT1, (C) GRP78, (D) p-PERK, (E) p-eIF2α, (F) CHOP and (G) caspase-12. (H) The mRNA levels of caspase-12 in the myocardium. Data are presented as the mean ± standard deviation. n=3. ##P<0.01 vs. Sham. *P<0.05 and **P<0.01 vs. MI/R. IOE, Inonotus obliquus extract; SIRT1, NAD-dependent protein deacetylase sirtuin-1; GRP78, glucose-regulated protein 78; PERK, protein kinase R-like endoplasmic reticulum kinase; eIF2α, eukaryotic translation initiation factor 2 subunit α; CHOP, C/EBP homologous protein; p, phosphorylated; MI/R, myocardial ischemia/reperfusion.

5). Dexmedetomidine at a dose of 1 µM attenuates H9c2 cardiomyocyte injury under 3 h of hypoxia exposure and 3 h of reoxygenation through the inhibition of endoplasmic reticulum stress. Experimental and Therapeutic Medicine (PubMed: 33376514) [IF=2.7]

Application: WB    Species:    Sample: myocardial cells

Figure 6. |Effects of DEX on the expression of GRP78, CHOP and caspase‑12 in myocardial cells treated under different conditions.(G) Representative western blots.Results are expressed as the mean ± standard deviation. *P<0.05 vs. Con; #P<0.05 vs. the H/R group; &P<0.05 vs. The DEX+H/R group.

Application: WB    Species: Rat    Sample: myocardial cells

Figure 6 Effects of DEX on the expression of GRP78, CHOP and caspase-12 in myocardial cells treated under different conditions. mRNA expression levels of (A) GRP78, (B) CHOP and (C) caspase-12, and protein expression levels of (D) GRP78, (E) CHOP and (F) caspase-12. (G) Representative western blots. Results are expressed as the mean ± standard deviation. *P<0.05 vs. Con; #P<0.05 vs. the H/R group; &P<0.05 vs. the DEX+H/R group. Con, control group; 1, normoxic incubation with DEX; 2, H/R incubation; 3, H/R incubation with dexmedetomidine; 4, normoxic incubation with 4-PBA; 5, H/R incubation with 4-PBA; 6, H/R incubation with DEX and 4-PBA; DEX, dexmedetomidine; GRP78, glucose-regulated protein 78; CHOP, C/EBP homologous protein; H/R, hypoxia/reoxygenation; 4-PBA, 4-phenylbutyric acid.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.